Identified as a culprit of a potential 'tripledemic' but with potential interventions on the horizon, RSV is this week's Clinical Trend.
against severe lower respiratory tract disease associated with RSV. Moderna has also begun a late-stage study of a messenger RNA RSV vaccine.has recommended marketing authorization
for nirsevimab , an immunization against RSV for newborns and infants. Nirsevimab is a long-acting antibody given as a single intramuscular injection. The US Food and Drug Administration granted nirsevimab breakthrough therapy designation in February 2019, although the product is still in the clinical trials stage and has not received marketing approval.
. Findings showed a 74.5% reduced incidence of medically attended lower respiratory tract infections associated with RSV in those receiving nirsevimab compared with placebo . The recommendation is now under review by the European Commission. Recent studies have showed the toll that RSV can take. It is the leading cause of US infant hospitalizations overall and across population subgroups,
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Children’s hospitals strained by surge in respiratory virusesChildren's hospitals are reporting an early surge in respiratory viruses, largely respiratory syncytial virus or RSV, overwhelming their emergency rooms and filling pediatric beds near capacity across the country.
Weiterlesen »
RSV surge: Pediatricians seeing more cases among older children (not just babies)Pediatricians say they usually they see the most cases of respiratory syncytial virus, or RSV, among children 2 and under, but now they're seeing a lot more older children getting exposed, too.
Weiterlesen »
Cases of Child RSV Are Swamping Hospitals. What Are the Symptoms, Treatments?Pediatricians’ offices, children’s hospitals, urgent care centers and emergency rooms across the United States are being overwhelmed by an early, heavy surge of respiratory syncytial virus (RSV) among infants and young children.
Weiterlesen »
Top U.S. official urges caution with RSV, vaccine in developmentWASHINGTON (Reuters) -U.S. officials are working on a respiratory syncytial virus (RSV) vaccine, but until one is available people should exercise caution, especially seniors and parents of young children, the nation's top infectious disease official said. A vaccine for the infectious respiratory disease will hopefully come within the next year or two, National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci told MSNBC in an interview. RSV is not a new virus but rising infections among young children are reportedly filling some U.S. hospitals to capacity at the same time as an earlier-than-normal influenza season and rising COVID cases are raising concerns about a 'tripledemic' this winter.
Weiterlesen »